Extended PBS access to ZOLADEX® (goserelin 3.6 mg implant) in Australia 

23 September 2026

AstraZeneca has announced that Zoladex (goserelin 3.6 mg implant) will remain on the Pharmaceutical Benefits Scheme (PBS) until 1 May 2027, after which it will move to a “supply only” arrangement. Prescriptions written before that date may continue to be dispensed for up to 12 months, enabling eligible patients to access PBS-subsidised treatment through to 1 May 2028. 

Please click here to read the letter from Astra Zeneca to PCPA.